FDA in July "public trial" Wendi Ya may increase the incidence
Release time: 2010-07-06 & nbsp & nbsp & nbsp Source:
GlaxoSmot (GSK) Disposal varieties of Diabetes Pharmaceutical Medicine Avandia again encountered question,Even market viewpoints My stake betting appare proposed,It is recommended that Wendi Ya retreat。Previous,For safety considerations,The EU has directly ordered "Portal"。
GSK China website information shows: "The American Food and Drug Administration (FDA) will be at the joint meeting of endocrinology and metabolic drugs and drug safety and risk management consultants in July,Announces all the new and existing data on the safety of the cardiovascular safety of Rogler (product name: Wendi)。”
Latest news,The specific time announced by the FDA is likely to be determined on July 13, local time in the United States、14th。But the current result is still difficult to predict。
Representative varieties of Roglerone drugs,Wendi Ya is mainly used to treat type 2 diabetes,Millions of patients in global use,Global sales of 2009 £ 462 million。
In our country,In March 2001, Tianjin Sike started production first,At present, single variety sales have spread all over the country,And has entered the medical insurance directory of some key provinces and regions。
My stake betting appBut in fact,Starting from 2005,Reports about Ventonia may increase the incidence of cardiovascular disease and repeatedly appear,Recently, there are even more news to point out,FDA discovered that Vinci is more harmful than similar drugs to the heart,A market view is proposed again,It is recommended that Wendi Ya retreat。
"Wenti Ya is in the varieties we are in key monitoring。"Du Xiaoxi, deputy director of the National Food and Drug Administration (SFDA) Drug Adverse Reactions Monitoring Center, told the First Financial Daily,In view of the continuous attention of the international community and public opinion on the safety of Wendi in recent years,SFDA has included Vinci into the drug variety of key monitoring。
She introduced,In two cases,SFDA will start the key monitoring of drugs,One is a data review based on historical monitoring,The varieties with high risk concerns are allocated into the key monitoring scope; there is also a based on other incentives,stake online sports bettingFor example, the safety rating raised by foreign related institutions,or clinicians have indeed reflected ??。
GSK responded to this newspaper yesterday: "Since the 2007 FDA joint consultant committee reviews the cardiovascular safety of Rogrely,Six clinical control trials have announced the results,Comprehensive consideration,These experiments show: Wendi Ya did not increase heart disease、The overall risk of stroke or death。”
At the same time,SFDA also said,I have not received relevant reports for Wendi Ya。
SFDA is currently paying close attention to the further research progress of Xibuquming,Now,Wenti Ya is also。
GSK China website information shows: "The American Food and Drug Administration (FDA) will be at the joint meeting of endocrinology and metabolic drugs and drug safety and risk management consultants in July,Announces all the new and existing data on the safety of the cardiovascular safety of Rogler (product name: Wendi)。”
Latest news,The specific time announced by the FDA is likely to be determined on July 13, local time in the United States、14th。But the current result is still difficult to predict。
Representative varieties of Roglerone drugs,Wendi Ya is mainly used to treat type 2 diabetes,Millions of patients in global use,Global sales of 2009 £ 462 million。
In our country,In March 2001, Tianjin Sike started production first,At present, single variety sales have spread all over the country,And has entered the medical insurance directory of some key provinces and regions。
My stake betting appBut in fact,Starting from 2005,Reports about Ventonia may increase the incidence of cardiovascular disease and repeatedly appear,Recently, there are even more news to point out,FDA discovered that Vinci is more harmful than similar drugs to the heart,A market view is proposed again,It is recommended that Wendi Ya retreat。
"Wenti Ya is in the varieties we are in key monitoring。"Du Xiaoxi, deputy director of the National Food and Drug Administration (SFDA) Drug Adverse Reactions Monitoring Center, told the First Financial Daily,In view of the continuous attention of the international community and public opinion on the safety of Wendi in recent years,SFDA has included Vinci into the drug variety of key monitoring。
She introduced,In two cases,SFDA will start the key monitoring of drugs,One is a data review based on historical monitoring,The varieties with high risk concerns are allocated into the key monitoring scope; there is also a based on other incentives,stake online sports bettingFor example, the safety rating raised by foreign related institutions,or clinicians have indeed reflected ??。
GSK responded to this newspaper yesterday: "Since the 2007 FDA joint consultant committee reviews the cardiovascular safety of Rogrely,Six clinical control trials have announced the results,Comprehensive consideration,These experiments show: Wendi Ya did not increase heart disease、The overall risk of stroke or death。”
At the same time,SFDA also said,I have not received relevant reports for Wendi Ya。
SFDA is currently paying close attention to the further research progress of Xibuquming,Now,Wenti Ya is also。
